Loading...
FDA logo

Fidia S.p.A.BIT:FDA Stock Report

Market Cap €4.7m
Share Price
n/a
1Y-97.3%
7D6.8%
1D0%
Portfolio Value
View

Fidia S.p.A.

BIT:FDA Stock Report

Market Cap: €4.7m

FDA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW484,853 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
484,853 investors already sharing narratives

Fidia S.p.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Fidia
Historical stock prices
Current Share Price€0.0094
52 Week High€0.39
52 Week Low€0.003
Beta0.36
1 Month Change38.24%
3 Month Change-34.72%
1 Year Change-97.27%
3 Year Change-99.90%
5 Year Change-99.90%
Change since IPO-99.90%

Recent News & Updates

Analysis Article Jun 13

Shareholders Shouldn’t Be Too Comfortable With Fidia's (BIT:FDA) Strong Earnings

Fidia S.p.A.'s ( BIT:FDA ) stock rose after it released a robust earnings report. However, we think that shareholders...
Analysis Article Sep 26

The Market Doesn't Like What It Sees From Fidia S.p.A.'s (BIT:FDA) Revenues Yet As Shares Tumble 27%

Unfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 27% in the last thirty days...

Recent updates

Analysis Article Jun 13

Shareholders Shouldn’t Be Too Comfortable With Fidia's (BIT:FDA) Strong Earnings

Fidia S.p.A.'s ( BIT:FDA ) stock rose after it released a robust earnings report. However, we think that shareholders...
Analysis Article Sep 26

The Market Doesn't Like What It Sees From Fidia S.p.A.'s (BIT:FDA) Revenues Yet As Shares Tumble 27%

Unfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 27% in the last thirty days...
Analysis Article Aug 01

Why Investors Shouldn't Be Surprised By Fidia S.p.A.'s (BIT:FDA) 34% Share Price Plunge

Fidia S.p.A. ( BIT:FDA ) shares have had a horrible month, losing 34% after a relatively good period beforehand. For...
Analysis Article May 26

Investors Aren't Buying Fidia S.p.A.'s (BIT:FDA) Revenues

Fidia S.p.A.'s ( BIT:FDA ) price-to-sales (or "P/S") ratio of 0.2x may look like a pretty appealing investment...
Analysis Article Oct 18

Investors Give Fidia S.p.A. (BIT:FDA) Shares A 34% Hiding

To the annoyance of some shareholders, Fidia S.p.A. ( BIT:FDA ) shares are down a considerable 34% in the last month...
Analysis Article Aug 29

It's Down 40% But Fidia S.p.A. (BIT:FDA) Could Be Riskier Than It Looks

Unfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 40% in the last thirty days...
Analysis Article Jun 20

Further Upside For Fidia S.p.A. (BIT:FDA) Shares Could Introduce Price Risks After 28% Bounce

Fidia S.p.A. ( BIT:FDA ) shares have continued their recent momentum with a 28% gain in the last month alone. Still...
Analysis Article May 28

Estimating The Fair Value Of Fidia S.p.A. (BIT:FDA)

Key Insights The projected fair value for Fidia is €0.84 based on 2 Stage Free Cash Flow to Equity Current share price...
Analysis Article Feb 13

Risks Still Elevated At These Prices As Fidia S.p.A. (BIT:FDA) Shares Dive 31%

Unfortunately for some shareholders, the Fidia S.p.A. ( BIT:FDA ) share price has dived 31% in the last thirty days...
Analysis Article Dec 23

Is Fidia (BIT:FDA) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article Oct 04

Fidia S.p.A.'s (BIT:FDA) Business Is Trailing The Industry But Its Shares Aren't

There wouldn't be many who think Fidia S.p.A.'s ( BIT:FDA ) price-to-sales (or "P/S") ratio of 0.3x is worth a mention...

Shareholder Returns

FDAIT MachineryIT Market
7D6.8%5.7%1.8%
1Y-97.3%0.4%25.2%

Return vs Industry: FDA underperformed the Italian Machinery industry which returned 0.4% over the past year.

Return vs Market: FDA underperformed the Italian Market which returned 25.2% over the past year.

Price Volatility

Is FDA's price volatile compared to industry and market?
FDA volatility
FDA Average Weekly Movement59.5%
Machinery Industry Average Movement5.9%
Market Average Movement4.7%
10% most volatile stocks in IT Market8.4%
10% least volatile stocks in IT Market3.0%

Stable Share Price: FDA's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: FDA's weekly volatility has increased from 32% to 60% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1974146Luigi Manigliowww.fidia.it

Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. The company offers HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; pushbutton panels; XPower digital drives for axis and spindle movement; and I/O Line input/output modules. It also provides software solutions include ViMill, an anti-collision solution; Machine Monitor, a software to monitor NC variables and parameters; Velocity 6, a solution for axes control to enhance the performances of the machine; HiMill, a CAM software for the machining of dies, models, and aeronautical components; Isograph solution, a user interface; and procedure-PRX, a solution for customized automation.

Fidia S.p.A. Fundamentals Summary

How do Fidia's earnings and revenue compare to its market cap?
FDA fundamental statistics
Market cap€4.69m
Earnings (TTM)€1.04m
Revenue (TTM)€30.56m
4.5x
P/E Ratio
0.2x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FDA income statement (TTM)
Revenue€30.56m
Cost of Revenue€11.49m
Gross Profit€19.07m
Other Expenses€18.03m
Earnings€1.04m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.0021
Gross Margin62.40%
Net Profit Margin3.40%
Debt/Equity Ratio74.2%

How did FDA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/08 00:15
End of Day Share Price 2026/07/08 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fidia S.p.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alberto FranceseIntesa Sanpaolo Equity Research
Sebastiano GrisettiIntesa Sanpaolo Equity Research